
Xavier Forns
Hepatology Services HepatologistFeatured publications
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Authors: Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M .Reference: Journal Of Hepatology 2019. -
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
Authors: Perpiñán E, Caro-Pérez N, García-González N, Gregori J, González P, Bartres C, Soria ME, Perales C, Lens S, Mariño Z, Londoño MC, Ariza X, Koutsoudakis G, Quer J, González-Candelas F, Forns X, Pérez-Del-Pulgar S .Reference: Journal Of Viral Hepatitis 2018. -
Shorter HBIG administration is not associated to HBV recurrence when receiving combined prophylaxis after liver transplantation.
Authors: Lens S, García-Eliz M, Fernández I, Castells L, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X .Reference: Liver International 2018. -
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Authors: Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X .Reference: Hepatology 2018. -
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
Authors: Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X .Reference: Journal Of Hepatology 2018. -
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
Authors: Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-Casals M, Hernández-Rodríguez J, Forns X .Reference: Gastroenterology 2018. -
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition
Authors: Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M.Reference: Journal Of Hepatology 2018. -
Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
Authors: Lens S, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC .Reference: Gastroenterology 2017. -
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Authors: Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ .Reference: Lancet Infectious Diseases 2017. -
EASL Recommendations on Treatment of Hepatitis C 2016
Authors: ;European Ass Study Liver.Reference: Journal Of Hepatology 2017.
Featured Projects
-
Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B
Principal investigator: Xavier Forns BernhardtFunder: Instituto de Salud Carlos IIICode: PI18/00079Duration: 01/01/2019 - 01/01/2022 -
Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños
Principal investigator: Xavier Forns BernhardtFunder: Ministerio de SanidadCode: 2020I018Duration: 01/01/2021 - 31/12/2022 -
TherVacB: A therapeutic vaccine to cure hepatitis B
Principal investigator: Xavier Forns BernhardtFunder: European CommissionCode: 848223Duration: 01/01/2020 - 31/12/2024 -
Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test
Principal investigator: Sabela Lens GarcíaFunder: GILEAD SCIENCES INCCode: IN-ES-987-5349Duration: 02/05/2018 - 31/03/2022